Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alfresa Holdings Corporation

Market Cap 399B 2.49B 2.16B 1.98B 1.86B 3.48B 238B 3.54B 23.37B 9.14B 115B 9.37B 9.17B P/E Ratio 2026
11x
P/E Ratio 2027 * 16.9x
Enterprise Value 399B 2.49B 2.16B 1.98B 1.86B 3.48B 238B 3.54B 23.37B 9.14B 115B 9.37B 9.17B EV / Sales 2026
0.15x
EV / Sales 2027 * 0.13x
Free-Float
88.28%
Yield 2026
2.69%
Yield 2027 * 3.23%
05-18 Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2026, has closed with 6,307,800 shares, representing 3.47% for ¥14,999.95 million. CI
05-18 Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2026. CI
05-15 Alfresa Holdings Corporation authorizes a Buyback Plan. CI
05-15 Alfresa Holdings Corporation announces an Equity Buyback for 6,307,800 shares, representing 3.46% for ¥14,999.95 million. CI
05-15 Alfresa Holdings Corp - to buy back up to 3.5% of own shares worth about 15 billion yen RE
05-15 Alfresa Holdings Corporation Announces Cash Dividend for the Year-End of the Fiscal Year Ended March 31, 2026, Payable on June 2, 2026; Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of the Fiscal Year Ending March 31, 2027 CI
05-15 Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Fiscal Year Ending March 31, 2027 CI
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
02-26 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Techno Suzuta, Co.,Ltd. from Onsendo, K.K. CI
02-10 Alfresa Books 15.4 Billion Yen Gain from Sale Of Investment Securities MT
02-10 Alfresa Holdings Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
02-02 ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
1 day-0.09%
1 week+0.09%
Current month-1.70%
1 month-6.27%
3 months-12.14%
6 months-9.51%
Current year-9.63%
1 week 2,190
Extreme 2190
2,242.5
1 month 2,106.5
Extreme 2106.5
2,409.5
Current year 2,106.5
Extreme 2106.5
2,685.5
1 year 1,923.5
Extreme 1923.5
2,685.5
3 years 1,897
Extreme 1897
2,685.5
5 years 1,505
Extreme 1505
2,685.5
10 years 1,505
Extreme 1505
3,350
Manager TitleAgeSince
Chief Executive Officer 63 -
Chief Tech/Sci/R&D Officer 63 2022-06-27
Corporate Officer/Principal 61 2020-03-31
Director TitleAgeSince
Director/Board Member 63 2007-05-31
Director/Board Member 65 2025-06-24
Director/Board Member 50 2020-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+0.09%+13.63%+0.55% 2.49B
+0.54%+3.06%-33.16%-11.84% 155B
+0.10%+3.05%-8.67%-4.06% 103B
+0.09%+6.77%-0.97%+57.94% 54.72B
-0.23%-6.71%+50.66%+49.87% 53.65B
-0.30%+1.19%-15.51%-41.41% 40.72B
+1.61%+7.72% - - 30.9B
+0.64%+3.41%-11.28%-39.48% 28.85B
-0.18%+4.44%+45.08%-5.15% 23.38B
-1.93%-0.66%-14.31%+2.17% 21.22B
Average -0.20%+2.35%+2.83%+0.95% 51.43B
Weighted average by Cap. +0.09%+2.28%-7.35%+1.43%

Financials

2026 2027 *
Net sales 3,099B 19.35B 16.73B 15.39B 14.43B 27.03B 1,848B 27.47B 181B 70.93B 896B 72.72B 71.17B 3,164B 19.77B 17.08B 15.72B 14.74B 27.61B 1,887B 28.06B 185B 72.43B 915B 74.26B 72.68B
Net income 37.04B 231M 200M 184M 173M 323M 22.09B 328M 2.17B 848M 10.71B 869M 851M 25.25B 158M 136M 125M 118M 220M 15.06B 224M 1.48B 578M 7.3B 592M 580M
Net Debt - -
Logo Alfresa Holdings Corporation
Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
Employees
12,452
Date Price Change Volume
26-06-11 2,197.00 ¥ -0.09% 520,700
26-06-10 2,199.00 ¥ -0.50% 619,200
26-06-09 2,210.00 ¥ 0.00% 358,800
26-06-08 2,210.00 ¥ +0.45% 443,500
26-06-05 2,200.00 ¥ 0.00% 409,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2,197.00JPY
Average target price
2,500.00JPY
Spread / Average Target
+13.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2784 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!